***LncRNA*** ***MEG3* promotes** **glaucomatous** **retinal ganglion cell apoptosis in acute glaucoma mice via up-regulating *miR-106* target gene *caspase-8***

Kai-di Sun, Jia-qi Wang, Qiu-li Zhang\*

\*Corresponding author: Qiuli Zhang

Affiliated Hospital of Inner Mongolia University for Nationalities, No. 1742, HuoLinHe Street, Tongliao, Neimenggu 028050, China.

TEL: +86-0475-8214451

E-mail:qiu\_lizhang@126.com

Running title: the pro-apoptotic effect of *MEG3* in glaucoma

**Abstract**

**Background** *MiR-106b* and *caspase-8* played a key role in the development of acute glaucoma. Increasing evidence has indicated that*long non-coding RNA (lncRNA) maternally expressed gene 3 (MEG3)* participated in regulating pathophysiological processes. However, the association among *MEG3*, *miR-106b* and *caspase-8* remained unclear.

**Methods** We employed the mouse model of acute glaucoma and oxygen and glucose deprivation (OGD)/reoxygenation cellular model for *in vivo* and *in vitro* experiments. The miRNA inhibitor and small interfering RNA (siRNA) were transfected into primary retinal ganglion cells (RGCs) for miRNA and lncRNA knockdown. The interaction among *MEG3*, *miR-106b* and *caspase-8* was assessed by RNA immunoprecipitation, RNA pull down and luciferase reporter assay. The changes in gene expression were assessed by quantitative Real-Time PCR (qRT-PCR) and western blot. Cell apoptosis analysis was performed using flow cytometry.

**Results** *MEG3* expression was increased in the mouse model of acute glaucoma and OGD-treated RGCs. *MEG3* knockdown alleviated RGC apoptosis following OGD. RNA immunoprecipitation and RNA pull down displayed that *MEG3* directly targeted *miR-106b*, and luciferase reporter assay confirmed the interaction between *miR-106b* and *caspase-8*. *MEG3* silencing significantly relieved RGC apoptosis via downregulating *miR-106b* target gene *caspase-8*.

**Conclusion** MEG3 increased the apoptosis of glaucomatous RGC via *miR-106b*/*caspase-8* axis.

# Keywords acute glaucoma; retinal ganglion cells; *MEG3*; *miR-106b*; *caspase-8*

**Introduction**

It is generally known that acute glaucoma is one of the leading causes of permanent vision loss and irreversible blindness worldwide, which is characterized by a rapid increase of intraocular pressure (IOP) resulting from a blockage around drainage canals and consequent retinal ischemia, leading to progressive damage to retinal ganglion cells (RGCs)[1,2]. Despite intensive medical treatment, increasing evidence has suggested that acute glaucoma continues progressing to blindness in quite a few patients[3]. Until recently, elevated IOP has been considered to be a major risk factor for the pathogenesis of RGC death in acute glaucoma[4]. Nevertheless, the detailed mechanisms by which elevated IOP ultimately led to RGC apoptosis were largely unknown.

In the past years, emerging evidence has showed that the caspase aspartate-specific cysteine protease family are involved in programmed cell death in eukaryotes[5]. Several studies have reported that caspase family consists of at least 14 members in mammalian cells. Caspase-8 is synthesized as a pro-enzyme and comprises a large N-terminal prodomain as well as a C-terminal catalytic domain, playing a crucial role in triggering death receptor-mediated apoptosis[6]. Recently, accumulating evidence has strongly implied that as an initiator caspase, caspase-8 has been implicated in acute glaucoma. For instance, Chi et al found that substantial rise in IOP induces Toll-like receptor 4 (TLR4)/caspase-8 signaling pathway activation, thereby leading to retinal ischemic injury and RGC death[7]. Furthermore, a recent report has indirectly revealed the apoptotic functions of caspase-8, demonstrating that high-mobility group box 1 (HMGB1) promotes the activation of caspase-8 via NF-κB pathway, resulting in inflammatory response[8].

MicroRNAs (miRNAs) are a class of small single-stranded (~22-nucleotide-long) non-coding RNAs that play important roles in physiopathologic processes by negatively regulating target genes. A number of dysregulated miRNAs have been actively involved in diverse biological processes. For example, Jamie et al reported that the miRNA cluster *miR-106b~25* promotes the proliferation of self-renewing neural stem/progenitor cell (NSPC) and the generation of new neurons under the condition of self-differentiation[9]. Hari et al have found the significant downregulation of *miR-106b* in glaucomatous retinae[10]. Nonetheless, the *miR-106b*-related molecular mechanisms were not well understood.

*MEG3*, an lncRNA, acts as a tumor suppressor in various cancers by influencing the apoptosis and proliferation of tumor cells, such as neuroblastomas and gliomas[11,12]. Previous reports have shown that *MEG3* expression is positively correlated with the progression of patients with retinoblastoma and inhibits tumor growth via *Wnt/β-catenin* pathway activation[13]. Besides the antineoplastic effect, other studies also indicated that the activation of *MEG3* triggers ischemic neuronal death[14]. However, little was known about the molecular mechanisms and biological roles of *MEG3* in acute glaucoma. Therefore, our study was designed to reveal whether *MEG3* affects acute glaucoma progression and ascertain the potential regulatory mechanism.

**Materials and Methods**

**Mouse model of acute glaucoma**

Animal experiments performed in this study were approved by the Animal Ethics Committee of the Affiliated Hospital of Inner Mongolia University for the Nationalities and qualify to the ARVO guidelines of animal use in eye research. Prior to *in vivo* experiment, a total of 30 adult male C57BL/6 mice obtained from Inner Mongolia University for the Nationalities were anesthetized by an intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine. The anterior chamber of the right eye was cannulated with a 30-gauge needle connected to a syringe filled with normal saline to maintain an IOP around 120 mmHg for 1h. Retinal ischemia was verified by the whitening of the iris and loss of the red reflex. After withdrawal of the needle, reperfusion occurred as IOP was normalized within 5 min measured by a noncontact tonometer (Nidek Co., Ltd., Aichi, Japan). The contralateral left eye as a control eye carried on sham-operated procedure. All mice were then subjected to 6, 24, 48, or 72 h of reoxygenation before euthanasia. Retinal tissues were collected for the following procedure.

**Isolation and culture of primary RGC**

Retinal tissues were isolated from enucleated eyeballs of 12-day-old newborn C57BL/6 mice and maintained in calcium/magnesium-free Hank’s balanced salt solution (Life Technologies, Carlsbad, CA, USA) containing 16.5 U/mL of papain (Sigma-Aldrich, St. Louis, MO, USA) for 30 min at room temperature. Primary RGCs were purified from the collected retinal cell suspension using two-step immunopanning (TSI) method as previously described[15] by incubation with rabbit-anti-mouse macrophage antibody (1:50; Fitzgerald Industries International, Concord, MA, USA) for 5 min and goat-anti-rabbit IgG antibody (1:200; Southern Biotechnology Associates, Birmingham, AL, USA) for 30 min at room temperature. All adherent RGCs were harvested by incubation with trypsin solution (Gibco, Carlsbad, CA, USA) and cultured in Dulbecco's modified eagle medium/Ham's F12 (DMEM/F12; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin (Gibco), and 100 μg/ml streptomycin (Gibco) at 37 °C in humidified 5% CO2 and 95% air.

**Oxygen and glucose deprivation (OGD) cellular model**

Primary RGCs were seeded on poly-L-ornithine and laminin precoated coverslips in 24-well plate with 2.5×105 cells per well and incubated at 37°C in humidified 5% CO2 and 95% air. Twenty-four hours after seeding, cells were washed twice with phosphate-buffered saline (PBS), cultured in glucose-free Roswell Park Memorial Institute (RPMI) 1640 medium containing L-glutamine and incubated in 5% CO2/95% N2 in an anaerobic chamber at 37°C for 4h. Subsequently, cells were then grown in DMEM/F12 containing glucose and returned to a normoxic environment (5% CO2 and 95% air) for another 12h at 37°C. In addition, RGCs exposed to normal culture media in a normoxic incubator were used as controls. OGD treated cells and controls were collected to qRT-PCR and western blotting analysis for MEG3, miR-106b and caspase-8 expression.

**RNA interference**

To investigate the biological role of *MEG3* in cellular ischemia/reperfusion (I/R) injury, primary RGCs were randomly divided into 4 groups: control, OGD, OGD+siRNA control (si-Ctrl) and OGD+siRNA-*MEG3* (si-*MEG3*). Briefly, cells were cultured in 96-well plates at 1×104 cells/well overnight, transfected with si-*MEG3* or si-Ctrl using X-tremeGENE siRNA Transfection Reagent (Roche Applied Science, Mannheim, Germany) following the manufacturer’s instructions and exposed to OGD treatment for 4h after 24h transfection. The sequence of si-*MEG3* was shown in the Table S1. The mRNA expression of *MEG3* was determined by qRT-PCR and cell apoptosis analysis was performed after 12h reoxygenation.

**RNA immunoprecipitation**

DIANA tools (http://carolina.imis.athena-innovation.gr/) were used to predict the potential interaction of *MEG3* and *miR-106b*. RIP assay was performed using Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA) according to the manufacturer’s instructions. RGCs at 80% density (approximately 1.0 × 107 cells) were washed with cold PBS and lysed with RIP lysis buffer at 4°C for 30min. Cell extracts were incubated with protein A/G sepharose beads conjugated to anti-Ago2 antibody (Millipore) or normal IgG at 4 °C and washed with lysis buffer for five times. Immunoprecipitated RNAs and total RNA from the whole cell lysates (input controls) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for western blotting or extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol for qRT-PCR analysis.

**RNA pull-down**

The interaction between *MEG3* and *miR-106b* was further examined by RNA pull-down using a Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s instructions. Protein extracts from RGCs (approximately 1.0 × 107 cells) were mixed with 50 pmol of biotinylated *MEG3* (or its negative control LOC) and incubated with 50µL of streptavidin magnetic beads 4℃ for 1h. The associated RNA-protein complex was isolated using Biotin Elution Buffer and boiled in SDS buffer for 10 min. The retrieved protein was detected using western blot analysis for Ago2 protein levels, while *miR-106b* mRNA levels were measured by qRT-PCR.

**Luciferase reporter assay**

Targetscan online bioinformatics software (http://www.targetscan.org) was used to identify the underlying binding sites of *miR-106b* and *caspase-8*. To verify the interaction between them, luciferase reporter assay was performed in RGCs. The *caspase-8* recombinant plasmids containg the wild type binding site of miR-106b (*caspase-8*-WT) or mutated binding site of miR-106b (*caspase-8*-Mut) were constructed, and then respectively co-transfected with *miR-106b* mimic or inhibitor or their corresponding negative controls into RGCs using Lipofectamine 2000 (Invitrogen, USA). Cells were harvested 24h post-transfection and were incubated with passive lysis buffer at room temperature for 10 minutes. Luciferase activity was measured using the Dual Luciferase Assay kit (Promega, Madison, WI, USA) following the manufacturer’s instructions.

**Cell transfection**

To further explore the molecular mechanism and biological function of *MEG3* in OGD-induced RGCs ischemic injury, primary RGCs were then randomized to 6 groups as follows: control, OGD, OGD+si-Ctrl, OGD+si-*MEG3*, OGD+si-*MEG3*+NC and OGD+si-*MEG3*+*miR-106b* inhibitor. Before transfection, cells were seeded in 6-well plates at a density of 4×105 cells/ml for one day. When cell confluence reached more than 70%, the miRNA inhibitor and small interfering RNA (siRNA) as well as negative controls (NC or si-Ctrl) purchased from GenePharma (Shanghai, China) were transfected into cells using a genefectine transfection reagent (Sigma-Aldrich). The sequences of *miR-106b* mimic and inhibitor were shown in the Table S2. After 24h transfection, cells were subjected to OGD/reoxygenation treatment followed by the subsequent experiments including *MEG3*, *miR-106b* and *caspase-8* expression and cell apoptosis.

**QRT-PCR analysis**

Total RNA was extracted from retinal tissues and RGCs using Trizol reagent and reverse-transcribed to cDNA using a PrimeScript RT Reagent Kit (TaKaRa, Dalian, China) according to the manufacturer’s protocol. The relative mRNA expression levels of MEG3, *miR-106b* and *caspase-8* were normalized to GAPDH, U6 and GAPDH snRNA expression, respectively, determined using SYBR Premix Ex Taq (TaKaRa) on an ABI 7500 Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) and calculated by the 2−ΔΔCt method. The primer sequences used for qRT-PCR were shown in the Table S2.

**Western blot**

For analysis of caspase-8 protein expression in retinal samples and RGCs, total protein was extracted using Radio-Immunoprecipitation Assay (RIPA) buffer (Beyotime, Shanghai, China), centrifuged with 14,000 rpm for 15 min at 4°C. Protein extracts and Prestained Protein Marker (Beyotime, China) were run on 10% SDS, transferred onto PVDF membranes and blocked with Tris buffered saline tween (TBST) containing 5% skim milk at room temperature for 2h. Blots were probed with rabbit anti-mouse caspase-8 polyclonal antibody (1:1000; Cell Signaling Technology, Boston, MA, USA) or β-actin mouse monoclonal antibody (1:1000; Beyotime, China) at 4°C overnight, incubated with horseradish-peroxidase (HRP)-coupled goat anti-rabbit IgG (1:2000; Abcam, Cambridge, UK) at room temperature for 1~2h and visualized on a Molecular Imager ChemiDoc XRS System (Bio-Rad Laboratories, Hercules, CA, USA) using an ECL Plus Western Blotting Substrate (Thermo Scientific, Shanghai, China).

**Cell apoptosis assay**

Cell apoptosis was analyzed by flow cytometry using Annexin V-FITC apoptosis detection kit (BD Biosciences; San Jose, CA, USA) according to the manufacturer’s protocols. Cells following transfection and OGD/reoxygenation treatment were collected, washed with cold PBS and stained with binding buffer containing Annexin V-FITC and propidine iodide (PI) at 4°C under darkness for 15 min. Finally, cells were recorded using flow cytometry (Beckman Coulter, Fullerton, CA, USA).

**Statistical analysis**

The data were expressed as mean ± standard deviation (SD). Statistical analyses were performed using SPSS version 22.0 (SPSS, Chicago, IL, USA). Significant differences between groups were analyzed using two-sided Student’s t test, and P<0.05 was considered to be statistically significant.

**Results**

***MEG3* and *caspase-8* was upregulated while *miR-106b* was downregulated in mouse model of acute glaucoma and OGD-treated RGCs**

To investigate the underlying role of *MEG3* in acute glaucoma, we examined *MEG3* as well as *miR-106b* and *caspase-8* expression in 6 paired high IOP-induced ischemic retinal tissues with different reperfusion time points (6, 24, 48 and 72h) and sham-operated contralateral tissues by qRT-PCR and western blot. Our data revealed that the expression of *MEG3* (Figure 1A, P<0.05) and *caspase-8* (Figure 1B, P<0.05) were elevated while *miR-106b* expression (Figure 1C, P<0.05) was decreased in ischemic retina at different time points after reperfusion relative to the sham-operated controls. Conformably, higher levels of *MEG3* (Figure 2A, P<0.05) and caspase-8 (Figure 2B, P<0.05) were observed, whereas, *miR-106b* was significantly downregulated (Figure 2C, P<0.05) in OGD/reoxygenation treated primary *RGCs* as compared with the normal cultured controls. Taken together, these data indicated that *MEG3*, *miR-106b* and *caspase-8* might be involved in the development of acute glaucoma.

***MEG3* knockdown suppressed OGD-induced RGC** **apoptosis**

To evaluate the biological functions of *MEG3*, the *MEG3* expression levels and apoptosis rate of RGCs following OGD and/or *MEG3* knockdown with siRNA transfection were analyzed by qRT-PCR and flow cytometry. Following OGD, the mRNA expression of *MEG3* (Figure 3A, P<0.05) and the percentage of apoptotic RGCs (Figure 3B, P<0.05) were markedly enhanced as compared with those of the normal control group. However, the knockdown of *MEG3* expression dramatically reduced the *MEG3* mRNA expression levels (Figure 3A, P<0.05) and the apoptosis rate of RGCs (Figure 3B, P<0.05) following OGD treatment. These findings demonstrated that *MEG3* inhibition reduced the apoptotic rate of RGCs *in vitro*.

***MEG3* targeted *miR-106b***

*MEG3* was reported to play important roles in post-transcriptional regulation in various cancers[16]. However, the specific downstream regulators involved in the abnormal expression of *MEG3* in acute glaucoma still remained unknown. Previously, our study has found that *MEG3* harbored one putative binding site for *caspase-8* predicted by the online DIANA tools (Figure 4A). The RNA immunoprecipitation and RNA pull-down assay were applied to confirm the potential binding protein. As shown in Figure 4B, *MEG3* and *miR-106b* enrichment was observed in Ago2-RNA precipitates, while less enrichment was found in IgG precipitates (P<0.05). Furthermore, RNA pull down assay revealed that the expression levels of *miR-106b* in *MEG3* pulled down pellet was higher than those of beads and loading control (Figure 4C, P<0.05). Together, these results demonstrated that *MEG3* targets *miR-106b*.

***MiR-106b* negatively regulated *caspase-8***

It was well known that *miR-106b* was a carcinogenic miRNA, in contrast, *caspase-8* acted as a tumor suppressor in cancers[17,18]. To explore whether *caspase-8* was a direct target of *miR-106b*, luciferase reporter assay was performed, since Targetscan software (http://www.targetscan.org) has predicted the interaction between *miR-106b* and *caspase-8* (Figure 5A). The results revealed that the *miR-106b* mimic decreased the luciferase activity (Figure 5B, P<0.05), while the *miR-106b* inhibitor elevated the luciferase activity (Figure 5C, P<0.05) in *caspase-8*-WT co-transfected system, conversely, this *caspase-8*-MUT scarcely responded to neither *miR-106b* mimic nor *miR-106b* inhibitor. In addition, *miR-106b* overexpression led to a decrease in the expression of *caspase-8* at mRNA and protein levels (Figure 5B, P<0.05), on the contrary, *miR-106b* inhibitor transfection reversed this trend (Figure 5C, P<0.05), suggesting that the direct binding existed between *miR-106b* and *caspase-8*.

***MEG3* exacerbated RGC apoptosis through *miR-106b*/*caspase-8* axis**

We further gained insights into the molecular mechanism by which *MEG3* knockdown inhibited RGC apoptosis. As expected, OGD treatment upregulated the expression of *MEG3* (Figure 6A, P<0.05) and *caspase-8* protein (Figure 6B, P<0.05), downregulated the mRNA expression of *miR-106b* (Figure 6C, P<0.05) and increased RGC apoptosis rate (Figure 6D, P<0.05), respectively. Nevertheless, *MEG3* knockdown resulted in a marked reduction in the expression of *MEG3* (Figure 6A, P<0.05) and *caspase-8* (Figure 6B, P<0.05) as well as the percentage of apoptotic RGCs (Figure 6D, P<0.05), but caused an elevated expression of *miR-106b* (Figure 6C, P<0.05), however, co-transfection of si-*MEG3* and *miR-106b* inhibitor led to an opposite effect. Conjointly, our results manifested that *MEG3* deteriorated cell apoptosis of RGCs through regulating *miR-106b*/*caspase-8* axis in acute glaucoma.

**Discussion**

Acute glaucoma is a momentously sight-threatening cause of non-reversible blindness worldwide featured with a sudden and extensive IOP increase, which in turn led to RGC apoptosis[19]. Increasing number of studies have demonstrated the fact that *MEG3* is aberrantly expressed in the pathogenesis and development of some tumors and functions as a novel tumor suppressor[20,21]. Hence, we speculated that *MEG3* might also play an underlying role in the development of acute glaucoma. In this study, we found that *MEG3* was upregulated in increased IOP-induced ischemic retinae following the mouse model of acute glaucoma as compared with the sham controls, which was consistent with a previous study showing that *MEG3* is expressed with higher levels following ischemia in adult mice[14]. Besides, it has recently been shown that the abnormal expression of *miR-106b* and *caspase-8* are observed in retinal ischemic injury[7,10], suggesting that they were the vital regulators in occurrence and progression of acute glaucoma. In our study, we also found a marked increase and decrease in the expression of *caspase-8* and *miR-106b*, respectively, in glaucomatous retinae. In the further *in vitro* experiments, we discovered that OGD treatment increased *MEG3* expression and *caspase-8* mRNA and protein expression while downregulated *miR-106b* mRNA expression in addition to facilitating RGC apoptosis.

To investigate the biological roles of *MEG3* in acute glaucoma, primary RGCs were transfected with si-*MEG3* or si-Ctrl following OGD/ reoxygenation treatment. Our current study showed that the knockdown of *MEG3* significantly resulted in a decrease of the percentage of apoptotic RGCs following OGD treatment *in vitro*, manifesting that *MEG3* might exert pro-apoptotic effect in glaucomatous RGCs. The aforementioned evidence has elucidated that *miR-106b* as well as *caspase-8* also have important roles in RGC apoptosis. Recently, evidence is emerging that lncRNAs are involved in regulation of downstream target miRNAs[22]. Therefore, investigations regarding the interaction between lncRNAs and miRNAs can deepen our understanding of the mechanisms underlying acute glaucoma. Therefore, we further explored the possible molecular mechanisms of *MEG3* action in RGCs. Interestingly, The RIP and RNA pull-down assay both confirmed that *MEG3* might be directly bind with *miR-106b* as expected. Our study further examined the interaction between *miR-106b* and *caspase-8* owing to existence of underlying binding sites of *miR-106b* and *caspase-8* predicted by Targetscan bioinformatics software. Luciferase reporter assay illustrated that *caspase-8* was a downstream target gene of *miR-106b*. What’s more, the overexpression of *miR-106b* suppressed *caspase-8* expression at mRNA and protein levels, while *miR-106b* knockdown upregulated *caspase-8* in RGCs. Since *MEG3* downregulated *miR-106b* by direct targeting *in vitro*, we assumed that *MEG3* might regulate *caspase-8* through m*iR-106b*.

To detect the correlation between *MEG3* and *caspase-8* in RGC apoptosis regulation, siRNA and miRNA inhibitor have been transfected into RGCs to knock down *MEG3* and *miR-106b*, respectively. We confirmed that *MEG3* and *caspase-8* were upregulated, whereas, *miR-106b* expression was inhibited by both *MEG3* and *miR-106b* knockdown after OGD treatment. In addition, the apoptosis of RGCs was promoted and the protein level of caspase-8 was up-regulated. These data indicated that *MEG3* promoted RGC apoptosis following ischemia/reperfusion (I/R) injury induced by OGD/reoxygenation via negatively regulating *miR-106b*, which in turn directly targeted *caspase-8*.

There are still two limitations in the current study. First, although we have detected the expression of *MEG3*, *miR-106b* and *caspase-8* in the mouse model of glaucoma and OGD/reoxygenation induced cell model, we have no data about their expressions in the retinas of patients with primary open-angle glaucoma (POAG). Second, although we have demonstrated that MEG3 promoted the apoptosis of OGD/ reoxygenation-induced RGC by regulating *miR-106b/caspase-8* pathway *in vitro*, the function of MEG3 in acute glaucoma have not be verified in vivo. Therefore, in the future, we will perform more in-depth study to improve the two shortfalls and make our study more clinically significant.

In summary, the present study authenticated for the first time that the interaction might exist among the *lncRNA MEG3*, *miR-106b* and *caspase-8* in increased IOP-induced acute glaucoma. *MEG*3 exacerbated ischemic RGC apoptosis via directly regulating *miR-106b*/*caspase-8* axis. Our research would deepen the understanding of the pathogenesis of acute glaucoma and provide a novel insight into seeking for the treatment strategy of it.

**References**

1. Wan, P., Su, W., Zhang, Y., Li, Z., Deng, C., and Zhuo, Y. (2017) Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway. Clinical Science131, CS20171182

2. Ha, Y., Liu, H., Xu, Z., Yokota, H., Narayanan, S. P., Lemtalsi, T., Smith, S. B., Caldwell, R. W., Caldwell, R. B., and Zhang, W. (2015) Endoplasmic reticulum stress-regulated CXCR3 pathway mediates inflammation and neuronal injury in acute glaucoma. Cell death & disease6, e1900

3. Quek, D. T., Koh, V. T., Tan, G. S., Perera, S. A., Wong, T. T., and Aung, T. (2011) Blindness and long-term progression of visual field defects in chinese patients with primary angle-closure glaucoma. American Journal of Ophthalmology152, 463-469

4. Ernawati, T., Suhendro, G., Sudiana, I. K., Putra, S. T., Harjanto, J. M., Sunarjo, Turchan, A., and Rantam, F. A. (2016) Hypoxic Preconditioning Improved Neuroprotective Effect of Bone Marrow-Mesenchymal Stem Cells Transplantation in Acute Glaucoma Models. Journal of Biomedical Science & Engineering09, 245-257

5. Kang, T. B., Benmoshe, T., Varfolomeev, E. E., Pewznerjung, Y., Yogev, N., Jurewicz, A., Waisman, A., Brenner, O., Haffner, R., and Gustafsson, E. (2004) Caspase-8 serves both apoptotic and nonapoptotic roles. Journal of Immunology173, 2976-2984

6. Zhang, Z. W., Li, H., Chen, S. S., Li, Y., Cui, Z. Y., and Ma, J. (2017) MicroRNA-122 regulates caspase-8 and promotes the apoptosis of mouse cardiomyocytes. Brazilian Journal of Medical & Biological Research50, e5760

7. Chi, W., Li, F., Chen, H., Wang, Y., Zhu, Y., Yang, X., Zhu, J., Wu, F., Ouyang, H., and Ge, J. (2014) Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1β production in acute glaucoma. Proceedings of the National Academy of Sciences of the United States of America111, 11181-11186

8. Wei, C., Chen, H., Li, F., Zhu, Y., Wei, Y., and Zhuo, Y. (2015) HMGB1 promotes the activation of NLRP3 and caspase-8 inflammasomes via NF-κB pathway in acute glaucoma. Journal of neuroinflammation12, 137

9. Brett, J. O., Renault, V. M., Rafalski, V. A., Webb, A. E., and Brunet, A. (2011) The microRNA cluster miR-106b~25 regulates adult neural stem/progenitor cell proliferation and neuronal differentiation. Aging3, 108-124

10. Jayaram, H., Cepurna, W. O., Johnson, E. C., and Morrison, J. C. (2015) MicroRNA Expression in the Glaucomatous Retina. Investigative Ophthalmology & Visual Science56, 7971

11. Tang, W., Dong, K., Li, K., Dong, R., and Zheng, S. (2016) MEG3, HCN3 and linc01105 influence the proliferation and apoptosis of neuroblastoma cells via the HIF-1α and p53 pathways. Scientific reports6, 36268

12. Wang, X., Zhou, L., and Liu, C. (2017) Expressions of LncRNA MEG3 and Prognosis in Gliomas. Liaoning Journal of Traditional Chinese Medicine

13. Gao, Y., and Lu, X. (2016) Decreased expression of MEG3 contributes to retinoblastoma progression and affects retinoblastoma cell growth by regulating the activity of Wnt/β-catenin pathway. Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine37, 1-1

14. Yan, H., Yuan, J., Gao, L., Rao, J., and Hu, J. (2016) Long noncoding RNA MEG3 activation of p53 mediates ischemic neuronal death in stroke. Neuroscience337, 191-199

15. Hong, S., Iizuka, Y., Chan, Y. K., and Gong, J. S. (2012) Isolation of primary mouse retinal ganglion cells using immunopanning-magnetic separation. Molecular Vision18, 2922

16. Zhuo, H., Tang, J., Lin, Z., Jiang, R., Zhang, X., Ji, J., Wang, P., and Sun, B. (2016) The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol Carcinog55, 209-219

17. Zheng, L., Zhang, Y., Liu, Y., Zhou, M., Lu, Y., Yuan, L., Zhang, C., Hong, M., Wang, S., and Li, X. (2015) MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. Journal of Translational Medicine13, 252

18. Pu, X., Storr, S. J., Zhang, Y., Rakha, E. A., Green, A. R., Ellis, I. O., and Martin, S. G. (2017) Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis22, 357

19. Su, W., Li, Z., Jia, Y., Zhu, Y., Cai, W., Wan, P., Zhang, Y., Zheng, S. G., and Zhuo, Y. (2017) microRNA-21a-5p/PDCD4 axis regulates mesenchymal stem cell-induced neuroprotection in acute glaucoma. Journal of Molecular Cell Biology

20. Zhou, Y., Zhang, X., and Klibanski, A. (2012) MEG3 noncoding RNA: a tumor suppressor. Journal of molecular endocrinology48, R45

21. Hu, D., Su, C., Jiang, M., Shen, Y., Shi, A., Zhao, F., Chen, R., Zhu, S., Bao, J., and Tang, W. (2016) Fenofibrate inhibited pancreatic cancer cells proliferation via activation of p53 mediated by upregulation of LncRNA MEG3. Biochemical & Biophysical Research Communications471, 290

22. Tang, Y., Jin, X., Xiang, Y., Chen, Y., Shen, C. X., Zhang, Y. C., and Li, Y. G. (2015) The lncRNA MALAT1 protects the endothelium against ox‐LDL‐induced dysfunction via upregulating the expression of the miR‐22‐3p target genes CXCR2 and AKT. FEBS letters589, 3189

**Figure legends**

Figure 1 Changes of gene expression in IOP-induced mouse model of acute glaucoma

1. Relative *MEG3* expression in ischemic retina at different time points (6, 24, 48 and 72h) after reperfusion and sham-operated retinal tissues using qRT-PCR.
2. The relative *caspase-8* expression at mRNA and protein levels in ischemic retina at different time points (6, 24, 48 and 72h) after reperfusion and sham-operated retinal tissues using qRT-PCR and western blot, respectively.
3. The relative mRNA expression of *miR-106b* in ischemic retina at different time points (6, 24, 48 and 72h) after reperfusion and sham-operated retinal tissues using qRT-PCR.

n= 6. \*P<0.05 compared with the sham group.

Figure 2 Changes of gene expression in OGD/reoxygenation induced I/R injury *in vitro*

1. Relative *MEG3* expression in RGC cells following OGD/reoxygenation treatment or normal culture (control).
2. The relative *caspase-8* expression at mRNA and protein levels in RGC cells following OGD/reoxygenation treatment or normal culture (control).

(C) The relative mRNA expression of *miR-106b* in RGC cells following OGD/reoxygenation treatment or normal culture (control).

\*P<0.05 compared with the control group.

Figure 3 Effect of *MEG3* on RGC apoptosis

1. Relative *MEG3* expression of RGCs in the group of control, OGD, OGD+si-Ctrl and OGD+si-*MEG3*.
2. The percentage of apoptotic RGCs in the group of control, OGD, OGD+si-Ctrl and OGD+si-*MEG3* detected by flow cytometry.

\*P<0.05 compared with the control group; #P<0.05 compared with OGD+si-Ctrl group.

Figure 4 *MEG3* targeted *miR-106b*

1. The binding sites on the *MEG3* and *miR-106b* predicted by DIANA tools.

(B) RIP experiment with anti-Ago2, IgG as negative control or 10% input as a positive control from RGC extracts using western blotting and qRT-PCR. \*P<0.05 compared with IgG group.

(C) Ago2 expression levels and enrichment of *miR-106b* expression after RNA pull-down experiment with RGC extracts in different groups. \*P<0.05 compared with beads and LOC group.

Figure 5 Effect of *miR-106b* on *caspase-8* expression

(A) The potential gene target of *miR-106b* predicted by mircoRNA.org online database.

(B) Relative luciferase activity of RGCs co-transfected with *miR-106b* mimic/pre-NC and *caspase-8*-3’UTR-WT or *caspase-8*-3’UTR-MUT plasmid.

The mRNA and protein expression levels of *caspase-8* in RGCs transfected with *miR-106b* mimic or pre-NC (control).

(C) Relative luciferase activity of RGCs co-transfected with *miR-106b* inhibitor/NC and *caspase-8*-3’UTR-WT or *caspase-8*-3’UTR-MUT plasmid.

The mRNA and protein expression levels of *caspase-8* in RGCs transfected with *miR-106b* inhibitor or NC (control).

\*P<0.05 compared with the control group.

Figure 6 The molecular regulation and biological functions of *MEG3* in OGD-induced I/R injury

1. Relative *MEG3* expression of RGCs in the group of control, OGD, OGD+si-Ctrl, OGD+si-*MEG3*, OGD+si-*MEG3*+NC and OGD+si-*MEG3*+*miR-106b* inhibitor.

(B) The relative *caspase-8* expression at protein levels of RGCs in the group of control, OGD, OGD+si-Ctrl, OGD+si-*MEG3*, OGD+si-*MEG3*+NC and OGD+si-*MEG3*+*miR-106b* inhibitor.

(C) The relative mRNA expression of *miR-106b* of RGCs in the group of control, OGD, OGD+si-Ctrl, OGD+si-*MEG3*, OGD+si-*MEG3*+NC and OGD+si-*MEG3*+*miR-106b* inhibitor.

(D) The percentage of apoptotic RGCs in the group of control, OGD, OGD+si-Ctrl, OGD+si-*MEG3*, OGD+si-*MEG3*+NC and OGD+si-*MEG3*+*miR-106b* inhibitor.

\*P<0.05 compared with the control group; #P<0.05 compared with OGD+si-Ctrl group; &P<0.05 compared with OGD+si-*MEG3*+NC group.